drugset / Trial / NCT05266807

Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence

NCT05266807

Phase 3 Recruiting 100 enrolled Benoit Guery
RandomizedParallel-groupOpen-labelTreatment

Summary

The clinical trial aims to evaluate the efficacy of fecal microbiota transplantation (FMT) after standard of care treatment (either vancomycin or fidaxomicin) vs the pragmatic use of standard of care treatment (either vancomycin or fidaxomicin) in severe and non-severe first episode and first recurrence of Clostridioides difficile infection (CDI). Experimental arm: antibiotic treatment (vancomycin or fidaxomicin as initially prescribed per SoC continued for 10 days) followed by FMT by oral capsules (one FMT, i.e. 20 FMT capsules given on 2 consecutive days, and followed by a 2nd FMT in severe CDI). Control Arm: vancomycin or fidaxomicin as initially prescribed per SoC continued for 10 days.

Timeline

Start
2023-03-15
Primary completion
2027-04-01
Completion
2028-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ornidazole Other / unclassified 20 unknown Oral
Background Fidaxomicin Other / unclassified 200 mg Oral
Background Vancomycin Other / unclassified 125 mg Oral